Altria Group Plans to Sell 35 Million Shares of AB InBev

Business by 2FIRSTS.ai
Mar.15.2024
Altria Group Plans to Sell 35 Million Shares of AB InBev
Altria Group plans to sell 35 million shares of Anheuser-Busch InBev for $2.26 billion, reducing its stake to 10%.

According to Reuters on March 14th, Altria Group plans to sell 35 million shares of Anheuser-Busch InBev. Altria currently owns approximately 197 million shares of Anheuser-Busch InBev, representing a 10% stake in the company.

 

On the recent stock market closing day, the total value of this equity sale was $2.26 billion. Anheuser-Busch InBev plans to sell a portion of its American depositary shares of Budweiser in the United States, as well as conduct a private placement in the European Economic Area and the United Kingdom.

 

Altria Group announced that Anheuser-Busch InBev has agreed to repurchase $2 billion worth of common stock directly from Altria after the equity offering concludes.

 

Altria Group owns several tobacco brands including Marlboro and the vape company NJOY, while Anheuser-Busch InBev is one of the largest beer producers in the world, headquartered in Belgium. It was formed by the merger of Anheuser-Busch and InBev in 2008. The company operates multiple well-known beer brands such as Budweiser, Corona, Stella Artois, and Hoegaarden. Anheuser-Busch InBev holds a significant market share globally and continues to expand its business operations.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Oklahoma DOC to allow inmates to buy nicotine vapes and pouches in 2026
Oklahoma DOC to allow inmates to buy nicotine vapes and pouches in 2026
Oklahoma’s Department of Corrections says it will begin allowing inmates to buy single-use nicotine vapes and nicotine pouches through prison canteens in 2026, framing the move as a strategy to reduce contraband-driven debts and prison violence. Officials say inmates will be barred from using personal nicotine products, the devices will be disposable and non-cartridge-based, and the program will be self-funded through inmate purchases rather than taxpayer money.
Feb.05 by 2FIRSTS.ai
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea’s Health Ministry says amendments to the Tobacco Business Act will take effect on April 24, bringing synthetic-nicotine e-liquid vapes under the legal definition of tobacco. The shift extends cigarette-style rules to these products, including mandatory graphic warnings, sharply limited advertising channels, stricter vending-machine placement requirements, and a ban on use in smoke-free areas, with enforcement checks slated from late April.
Feb.03 by 2FIRSTS.ai
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
Tamarind Intelligence’s decision to appoint a technology-sector executive as chief executive officer signals more than a leadership reshuffle at a specialist data firm. It reflects a broader structural shift across the global nicotine industry, where companies, regulators and intelligence providers are embedding artificial intelligence into core operations.
Special Report
Feb.18
Russia’s Duma Deputy Speaker Davankov calls for a total vape ban, citing drug sales disguised as vapes
Russia’s Duma Deputy Speaker Davankov calls for a total vape ban, citing drug sales disguised as vapes
Vladislav Davankov, deputy speaker of Russia’s State Duma, urged a nationwide ban on vapes, arguing it would help prevent drugs being sold under the cover of vaping products, including near schools. The remarks come as Russia prepares to enforce a separate ban on vape sales at public transport stops starting Sept. 1, 2026.
Feb.09 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24